Some brighter views
21/06/22 -"We have revised our models and included all figures. We have become more optimistic about Kabi’s profitability (IV drug’s brake to earnings sorted) and allowed for Helios’ higher than anticipated ..."
Pages
55
Language
English
Published on
21/06/22
You may also be interested by these reports :
10/10/25
Key conclusions: Chinese manufacturers can produce Meta Rayban-like glasses for €25. The margin dilution impact of Meta Ray-Ban is probably lower ...
10/10/25
We have removed the long term margin dilution from Meta Ray-Ban in our model as we think the dilution won’t be as significant as we had previously ...
08/10/25
Sartorius is scheduled to report its Q3 2025 earnings on the 16th of October. Interestingly, the stock has surged c. 14% from 30 September to 7 ...
02/10/25
Ostensibly, it’s difficult to make an investment case for a firm, which has eroded >30% of shareholders’ wealth over five years. For Fresenius ...